Literature DB >> 31813809

Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.

Renzo G DiNatale1, Alexander N Gorelick2, Vladimir Makarov3, Kyle A Blum4, Andrew W Silagy4, Benjamin Freeman4, Diego Chowell3, Julian Marcon4, Roy Mano4, Alex Sanchez4, Kyrollis Attalla4, Stanley Weng4, Martin Voss5, Robert J Motzer5, Paul Russo4, Jonathan A Coleman4, Victor E Reuter6, Ying-Bei Chen6, Timothy A Chan3, Ed Reznik7, Satish K Tickoo8, A Ari Hakimi9.   

Abstract

BACKGROUND: TCEB1-mutant renal cell carcinoma (RCC) is a rare variant of RCC with clear-cell features. Owing to its unique morphological and molecular features it has recently been proposed as a separate entity. Initial series suggested an indolent, early-stage phenotype. Here we expand our clinical cohort and describe a more detailed genomic analysis looking for potential drivers of aggressiveness. DESIGN, SETTING, AND PARTICIPANTS: We identified five new cases in our institutional sequencing cohort, four of whom were found to have high-stage disease (American Joint Committee on Cancer stage III/IV). Twelve previously reported cases were pooled for comparison purposes (Sato, The Cancer Genome Atlas, TRACERx Renal). OUTCOME MEASURES AND STATISTICAL ANALYSIS: We used our previously validated pipeline to analyze somatic mutations and copy number alterations (CNAs) in seven tumor samples with available data and estimated the number of cancer cells bearing each somatic mutation. The oncogenic potential of mutations was assessed using OncoKB and two other algorithms. Mann-Whitney U tests were used to evaluate differences in genomic markers between stage groups. RESULTS AND LIMITATIONS: All tumors showed biallelic inactivation of the TCEB1 gene according to a combination of somatic mutation and CNA analyses. Mutations were always found in residues involved in hydrophobic interactions with VHL. We found that high-stage tumors had additional oncogenic mutations (median 1, interquartile range [IQR] 1-1 vs 2, IQR 2-2; median difference 1, 95% confidence interval [CI] 1-1; p= 0.002) and showed whole-genome doubling events. They also seemed to have a higher burden of somatic CNAs (median fraction CNA genome 0.10, IQR 0.10-0.15 vs 0.63, IQR 0.58-0.68), however, this finding did not reach statistical significance (median difference 0.49, 95% CI 0.33-0.63; p=0.052).
CONCLUSIONS: TCEB1-mutant RCC can show variable behavior ranging from very indolent to aggressive. Specific molecular events leading to high genomic instability seem to be associated with aggressiveness. This study expands the clinical spectrum of TCEB1-mutant RCC. PATIENT
SUMMARY: We present four cases of aggressive TCEB1-mutant renal cell carcinoma, a rare type of kidney cancer. In-depth analysis of the genomes of these tumors revealed certain abnormalities that might explain this aggressive behavior.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA mutational analysis; Genomic instability; Metastasis; Renal cell carcinoma; Tumor suppressor genes

Mesh:

Substances:

Year:  2019        PMID: 31813809      PMCID: PMC7274909          DOI: 10.1016/j.euf.2019.11.013

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  28 in total

1.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

2.  Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.

Authors:  Y Takagi; A Pause; R C Conaway; J W Conaway
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

3.  Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.

Authors:  Henry C Nguyen; Haitao Yang; Jennifer L Fribourgh; Leslie S Wolfe; Yong Xiong
Journal:  Structure       Date:  2015-02-05       Impact factor: 5.006

4.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

5.  Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.

Authors:  Jozefina Casuscelli; Maria F Becerra; Brandon J Manley; Emily C Zabor; Ed Reznik; Almedina Redzematovic; Maria E Arcila; Daniel M Tennenbaum; Mazyar Ghanaat; Mahyar Kashan; Christian G Stief; Maria Carlo; Martin H Voss; Darren R Feldman; Robert J Motzer; Yingbei Chen; Victor E Reuter; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi
Journal:  Eur Urol Focus       Date:  2017-09-24

6.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Authors:  Christopher J Ricketts; Aguirre A De Cubas; Huihui Fan; Christof C Smith; Martin Lang; Ed Reznik; Reanne Bowlby; Ewan A Gibb; Rehan Akbani; Rameen Beroukhim; Donald P Bottaro; Toni K Choueiri; Richard A Gibbs; Andrew K Godwin; Scott Haake; A Ari Hakimi; Elizabeth P Henske; James J Hsieh; Thai H Ho; Rupa S Kanchi; Bhavani Krishnan; David J Kwiatkowski; Wembin Lui; Maria J Merino; Gordon B Mills; Jerome Myers; Michael L Nickerson; Victor E Reuter; Laura S Schmidt; C Simon Shelley; Hui Shen; Brian Shuch; Sabina Signoretti; Ramaprasad Srinivasan; Pheroze Tamboli; George Thomas; Benjamin G Vincent; Cathy D Vocke; David A Wheeler; Lixing Yang; William Y Kim; A Gordon Robertson; Paul T Spellman; W Kimryn Rathmell; W Marston Linehan
Journal:  Cell Rep       Date:  2018-06-19       Impact factor: 9.423

Review 7.  Resolving genetic heterogeneity in cancer.

Authors:  Samra Turajlic; Andrea Sottoriva; Trevor Graham; Charles Swanton
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

8.  Predicting the functional impact of protein mutations: application to cancer genomics.

Authors:  Boris Reva; Yevgeniy Antipin; Chris Sander
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

9.  A systematic analysis of atomic protein-ligand interactions in the PDB.

Authors:  Renato Ferreira de Freitas; Matthieu Schapira
Journal:  Medchemcomm       Date:  2017-09-26       Impact factor: 3.597

10.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

Authors:  Matthew T Chang; Saurabh Asthana; Sizhi Paul Gao; Byron H Lee; Jocelyn S Chapman; Cyriac Kandoth; JianJiong Gao; Nicholas D Socci; David B Solit; Adam B Olshen; Nikolaus Schultz; Barry S Taylor
Journal:  Nat Biotechnol       Date:  2015-11-30       Impact factor: 54.908

View more
  5 in total

Review 1.  [Histological subtypes of renal cell carcinoma : Overview and new developments].

Authors:  I Polifka; A Agaimy; H Moch; A Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

Review 2.  Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.

Authors:  Alessia Cimadamore; Liang Cheng; Marina Scarpelli; Francesco Massari; Veronica Mollica; Matteo Santoni; Antonio Lopez-Beltran; Rodolfo Montironi; Holger Moch
Journal:  Transl Androl Urol       Date:  2021-03

Review 3.  Mutation Profile Variability in the Primary Tumor and Multiple Pulmonary Metastases of Clear Cell Renal Cell Carcinoma. A Review of the Literature and Analysis of Four Metastatic Cases.

Authors:  Kristyna Prochazkova; Nikola Ptakova; Reza Alaghehbandan; Sean R Williamson; Tomáš Vaněček; Josef Vodicka; Vladislav Treska; Joanna Rogala; Kristyna Pivovarcikova; Kvetoslava Michalova; Maryna Slisarenko; Milan Hora; Michal Michal; Ondrej Hes
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

4.  The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.

Authors:  Stanley Weng; Renzo G DiNatale; Andrew Silagy; Roy Mano; Kyrollis Attalla; Mahyar Kashani; Kate Weiss; Nicole E Benfante; Andrew G Winer; Jonathan A Coleman; Victor E Reuter; Paul Russo; Ed Reznik; Satish K Tickoo; A Ari Hakimi
Journal:  Eur Urol       Date:  2020-10-10       Impact factor: 20.096

5.  Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.

Authors:  Avgi Andreou; Bryndis Yngvadottir; Laia Bassaganyas; Graeme Clark; Ezequiel Martin; James Whitworth; Alex J Cornish; Richard S Houlston; Philip Rich; Catherine Egan; Shirley V Hodgson; Anne Y Warren; Katie Snape; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2022-08-23       Impact factor: 5.121

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.